The Institute for Clinical and Economic Review’s (ICER’s) Evidence Rating Matrix is a comparative clinical effectiveness decision tool that distills an intervention’s net health benefit its uncertainty into ordered categorical grades. ICER assessments also estimate incremental lifetime quality-adjusted life years (QALYs) through cost-effectiveness modeling. This analysis aims to explore the rel...

Abstract The relationship between costs and health benefits of branded pharmaceuticals remains controversial. This paper examines the incremental incurred for gained from largest available sample cost-effectiveness studies drugs in USA, 1994–2015 Tufts Registry Cost-Effectiveness Analyses. Earlier used small, specialized samples drugs. We use linear regression analysis to estimate association t...

Objectives To assess the cost-effectiveness of uterine artery embolisation (UAE) and myomectomy for women with symptomatic fibroids wishing to avoid hysterectomy. Design Economic evaluation alongside FEMME randomised controlled trial. Setting 29 UK hospitals. Population Premenopausal who had amenable UAE or 254 were (127) (127). Methods A within-trial cost–utility analysis was conducted from pe...

BACKGROUND The objective of this analysis was to evaluate the cost-effectiveness of using bendamustine versus alemtuzumab or bendamustine versus chlorambucil as a first-line therapy in patients with Binet stage B or C chronic lymphocytic leukemia (CLL) in the US. METHODS A discrete event simulation of the disease course of CLL was developed to evaluate the economic implications of single-agen...

Treatment of chronic hepatitis C with Interferon (IFN) alpha2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality-adjusted life years ($/QAL...

Objective Screening psoriasis patients for psoriatic arthritis (PsA) is intended to identify at earlier stages of the disease. Early treatment expected slow disease progression and delay need biologic therapy. Our objective was determine cost-effectiveness screening PsA in with Canada. Methods A Markov model built estimate costs quality-adjusted life years (QALYs) tools patients. The included T...

Measuring and modeling patient quality of life is critically important in the evaluation cost-effectiveness any health intervention, with arguably being most consideration patients for whom a meaningful extension not feasible. In present study, we aimed to identify cost-utility analyses comparing selective internal radiation therapy (SIRT) systemic unresectable hepatocellular carcinoma (HCC) co...

BACKGROUND The cost-effectiveness of enzyme replacement therapy (ERT) compared to standard medical care was evaluated in the Dutch cohort of patients with Fabry disease. METHODS Cost-effectiveness analysis was performed using a life-time state-transition model. Transition probabilities, effectiveness data and costs were derived from retrospective data and prospective follow-up of the Dutch st...

BACKGROUND Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications. In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, weight, blood pressure (BP), and lipids in patients with T2DM. We simulated potential effects of ExQW on vascular complications, survival, and medical costs over 20 years versus standard therapies. PATIENTS AND METHODS T...